![]() ![]() “It is thanks to the endless efforts and contribution of study participants and staff across the UK that we can keep discovering more about the use of vaccines, and they continue to play a pivotal role just as they have done throughout the pandemic.” These new study findings support that decision and provides the public with the confidence that fourth doses are both safe and even more effective than third doses at boosting immunity against COVID-19. “We knew that it was important to offer a fourth dose to those most vulnerable earlier in the year. “The study's latest results once again show the importance of sustained research into COVID-19 vaccines and how they are best used to keep the virus at bay. Professor Andrew Ustianowski, NIHR Clinical Lead for the COVID-19 Vaccination Programme and Joint National Infection Specialty Lead, said: “The COV-BOOST study has continuously supported the UK's booster vaccination programme and had further impact on how vaccines are administered globally. The two vaccines trialled in the fourth dose sub-study were those deployed in the UK NHS third dose booster campaign: While pain at vaccination site and fatigue were the most common side effects, there were no vaccine-related serious adverse events, and fourth doses were safe and well tolerated. These were approximately seven months after their third dose. In the fourth dose study, 166 people who had received a third dose of Pfizer, following Pfizer or AstraZeneca initial doses in June 2021, were randomised to receive full dose Pfizer or half dose Moderna as a fourth dose. The study was key to shaping the UK’s 2021 autumn booster programme and gives vital evidence for global vaccination efforts. ![]() “We’re able to live with Covid thanks to the protection provided by our phenomenal vaccine programme and a booster dose will top up your immunity to continue to keep you and your loved ones safe.”ĬOV-BOOST provided the world’s first data on the safety, immune responses and side-effects of third dose in mix and match schedules. Health and Social Care Secretary Sajid Javid, said: “This is further evidence underlining the importance of people coming forward for their booster as soon as they are eligible. Professor Saul Faust, trial lead and Director of the NIHR Southampton Clinical Research Facility, said: “These results underline the benefits of the most vulnerable people receiving current spring boosters and gives confidence for any prospective autumn booster programme in the UK, if the Joint Committee on Vaccination and Immunisation considers it needed at that time.” They are also effective at increasing both antibody and cellular immunity up to and above baseline and peak levels observed following third dose boosters. The latest COV-BOOST findings now show that fourth dose mRNA booster vaccines for COVID-19 are well-tolerated in people who received Pfizer as a third dose. ![]() A wider group of people may be offered a fourth dose booster later this year. This has been a precautionary strategy to maintain high levels of immunity prior to the study data being available. Researchers have published their findings today in The Lancet Infectious Diseases.įourth doses of COVID-19 vaccines have been offered as a spring booster for those most vulnerable in the UK. ![]() The latest results from the COV-BOOST trial, led by University Hospital Southampton, show that a fourth dose mRNA vaccine is safe and boosts antibody levels - even higher than that of a third dose. COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide study. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |